Repression of <i>SLC22A3</i> by the AR-V7/YAP1/TAZ axis in enzalutamide-resistant castration-resistant prostate cancer

Citations

WEB OF SCIENCE

8
Citations

SCOPUS

8

초록

Metastatic castration-resistant prostate cancer (mCRPC) is an aggressive and fatal disease, with most patients succumbing within 1-2 years despite undergoing multiple treatments. Androgen-receptor (AR) inhibitors, including enzalutamide (ENZ), are used for the treatment of mCRPC; however, most patients develop resistance to ENZ. Herein, we propose that the repression of SLC22A3 by AR-V7/YAP1/TAZ conferred ENZ resistance in mCRPC. SLC22A3 expression is specifically downregulated in the ENZ-resistant C4-2B MDVR cells, and when YAP1/TAZ is hyperactivated by AR full-length or AR-V7, these proteins interact with DNMT1 to repress SLC22A3 expression. We observed low SLC22A3 expression and high levels of TAZ or YAP1 in mCRPC patient tissues harbouring AR-V7 and the opposite expression patterns in normal patient tissues. Our findings suggest a mechanism underlying ENZ resistance by providing evidence that the AR-V7/YAP1/TAZ axis represses SLC22A3, which could be a potential treatment target in prostate cancer.

키워드

AR-V7; enzalutamide resistance; TAZ; YAP1; ORGANIC CATION TRANSPORTERS; ANDROGEN RECEPTOR; INCREASED SURVIVAL; METFORMIN; TAZ; YAP; VARIANTS; ABIRATERONE; EFFECTORS; STEMNESS
제목
Repression of <i>SLC22A3</i> by the AR-V7/YAP1/TAZ axis in enzalutamide-resistant castration-resistant prostate cancer
저자
Seo, Eunjeong; Jee, Byula; Chung, Jae Hoon; Song, Wan; Sung, Hyun Hwan; Jeon, Hwang Gyun; Jeong, Byong Chang; Seo, Seong Il; Jeon, Seong Soo; Lee, Hyun Moo; Kang, Minyong
DOI
10.1111/febs.16657
발행일
2023-03
유형
Article
저널명
FEBS Journal
권
290
호
6
페이지
1645 ~ 1662